AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15190527 — intervention group
Group type: COMPARATOR
Intervention: MVR surgery alone
Number of subjects: 300
Study 12184424 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐file or K‐Nitiflex file (step‐back technique)
Number of subjects: 40
Study 12184424 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐reamer (standardization technique)
Number of subjects: 40
Study 12184424 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation only
Number of subjects: 40
Study 12184424 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 9615870 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restricted diet (75% kcal)
Number of subjects: 0
Study 9615870 — intervention group
Group type: COMPARATOR
Intervention: Maintenance energy diet (100% kcal)
Number of subjects: 0
Study 7653770 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg intravenously 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and droperidol 0.05 mg.ml‐1
Number of subjects: 50
Study 7653770 — intervention group
Group type: COMPARATOR
Intervention: Cyclizine 50 mg by slow intravenous injection 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and cyclizine 2 mg.ml‐1
Number of subjects: 50
Study 2583908 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA therapy
Number of subjects: 12
Study 338024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol, 2 mg
Number of subjects: 0
Study 338024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestriol, 1 mg
Number of subjects: 0
Study 338024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29509645 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call before UDS appointment
Number of subjects: 102
Study 29509645 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no telephone call)
Number of subjects: 102
Study 29154060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesfytol® (1 tablet/day)
Number of subjects: 642
Study 25745750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Number of subjects: 90
Study 25745750 — intervention group
Group type: COMPARATOR
Intervention: Traditional hysteroscopy
Number of subjects: 90
Study 23077975 — intervention group
Group type: EXPERIMENTAL
Intervention: False isolated-office RH (elevated clinic BP, controlled awake SBP/DBP means, but elevated asleep SBP or DBP mean)
Number of subjects: 3042
Study 23077975 — intervention group
Group type: EXPERIMENTAL
Intervention: True isolated-office RH (elevated clinic BP and controlled awake and asleep ambulatory BPs)
Number of subjects: 3042
Study 23077975 — intervention group
Group type: EXPERIMENTAL
Intervention: True RH (elevated awake or asleep SBP/DBP means while treated with 3 medications, or any patient treated with ≥4 medications)
Number of subjects: 3042
Study 20573655 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (IV injection of two 0.4 mg ampules)
Number of subjects: 116
Study 20573655 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 116
Study 19880280 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion (CV)
Number of subjects: 366
Study 19880280 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach without TEE
Number of subjects: 366
Study 16533781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg orally once daily (arm A)
Number of subjects: 80
Study 16533781 — intervention group
Group type: COMPARATOR
Intervention: 1,200 mg orally twice daily (arm B)
Number of subjects: 80
Study 16533781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 80
Study 15545973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by tamoxifen for 5 years
Number of subjects: 1669
Study 15545973 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen for 5 years
Number of subjects: 1669
Study 15545973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 1669
Study 10903249 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA‐Monobloc
Number of subjects: 24
Study 10903249 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA‐Herbst
Number of subjects: 24
Study 10903249 — intervention group
Group type: COMPARATOR
Intervention: No appliance
Number of subjects: 24
Study 9120789 — intervention group
Group type: EXPERIMENTAL
Intervention: Large monetary reward for novel performance
Number of subjects: 416
Study 9120789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward for novel performance
Number of subjects: 416
Study 9120789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward for uncreative performance
Number of subjects: 416
Study 8463435 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 60 mg diltiazem
Number of subjects: 18
Study 8463435 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 60 mg three times a day for 3 days
Number of subjects: 18
Study 8463435 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 60 mg three times a day for 6 days
Number of subjects: 18
Study 3903868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0
Study 31390641 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine care (TC)
Number of subjects: 75
Study 31390641 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 75
Study 30043039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (n=191)
Number of subjects: 394
Study 30043039 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) (n=203)
Number of subjects: 394
Study 30043039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (n=41)
Number of subjects: 394
Study 30043039 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) (n=38)
Number of subjects: 394
Study 30043039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab
Number of subjects: 394
Study 30043039 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 394
Study 27412638 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Ward Care (KWC)
Number of subjects: 141
Study 27412638 — intervention group
Group type: COMPARATOR
Intervention: Intermediate Intensive Care (IIC)
Number of subjects: 141
Study 24859122 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program consisting of breast massage and 1:1 breastfeeding education, counseling, and support for 10 days
Number of subjects: 70
Study 24859122 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 70
Study 22391283 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 60
Study 22391283 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study 20109275 — intervention group
Group type: EXPERIMENTAL
Intervention: Above average students
Number of subjects: 382
Study 20109275 — intervention group
Group type: COMPARATOR
Intervention: Average students
Number of subjects: 382
Study 20109275 — intervention group
Group type: EXPERIMENTAL
Intervention: Below average students
Number of subjects: 382
Study 18313127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/d
Number of subjects: 15
Study 18313127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15827314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc9-MenC (n = 120)
Number of subjects: 240
Study 15827314 — intervention group
Group type: COMPARATOR
Intervention: MenC (n = 120)
Number of subjects: 240
Study 12055580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (0.5 mg)
Number of subjects: 28
Study 12055580 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 28
Study 10982577 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially developed pamphlet
Number of subjects: 714
Study 10982577 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA's 'A citizen's guide to radon'
Number of subjects: 714
Study 10982577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone counselling
Number of subjects: 714
Study 10982577 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially developed pamphlet plus brief telephone counselling
Number of subjects: 714
Study 9124917 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior septal approach
Number of subjects: 146
Study 9124917 — intervention group
Group type: COMPARATOR
Intervention: Conventional left atriotomy
Number of subjects: 146
Study 8442622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted self-quit training
Number of subjects: 3161
Study 8442622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted group referral
Number of subjects: 3161
Study 8442622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted combination of self-quit training and referral
Number of subjects: 3161
Study 8442622 — intervention group
Group type: COMPARATOR
Intervention: Brief physician advice alone
Number of subjects: 3161
Study 3009292 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 15
Study 3009292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 15
Study 3009292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29175067 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol (528 women)
Number of subjects: 1023
Study 29175067 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist protocol (495 women)
Number of subjects: 1023
Study 27529375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-60 mg/d or 80-120 mg/d)
Number of subjects: 142
Study 27529375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/d)
Number of subjects: 142
Study 27529375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 23912215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless THA
Number of subjects: 62
Study 23912215 — intervention group
Group type: COMPARATOR
Intervention: Cemented THA
Number of subjects: 62
Study 23912215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 22388491 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (doses of 2, 4, 6, 8, and 10 mg·kg bm(‐1))
Number of subjects: 17
Study 22388491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 17
Study 22388491 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 17
Study 22388491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20102356 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 5 mg once daily
Number of subjects: 148
Study 20102356 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5 mg once daily
Number of subjects: 148
Study 20102356 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg once daily
Number of subjects: 148
Study 20102356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 17262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate at a dose of 440 mg/m²/day for 28 days
Number of subjects: 70
Study 17262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 70
Study 16846420 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 120
Study 16846420 — intervention group
Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 120
Study 16846420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 12784170 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric voluntary contraction and flexibility measured with specific ergometers; muscle stiffness measured using quick-release movements of the wrist.
Number of subjects: 0
Study 12784170 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility assessments in both women groups; training-induced increase for wrist extension.
Number of subjects: 0
Study 12784170 — intervention group
Group type: EXPERIMENTAL
Intervention: Women active joint flexibility and musculo-tendinous stiffness indices.
Number of subjects: 0
Study 10770462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.5 mg twice daily)
Number of subjects: 64
Study 10770462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8777275 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of IL‐1 beta in gingival crevicular fluid (GCF) and inflamed gingival specimens using ELISA.
Number of subjects: 14
Study 8777275 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF flow measurement.
Number of subjects: 14
Study 8777275 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of IL‐1 beta concentration with tissue pathology.
Number of subjects: 14
Study 29716819 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-Dose Inhaler (MDI)
Number of subjects: 890
Study 29716819 — intervention group
Group type: COMPARATOR
Intervention: Breath Actuated Nebulizer (BAN)
Number of subjects: 890
Study 29716819 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis for MDI
Number of subjects: 890
Study 29716819 — intervention group
Group type: COMPARATOR
Intervention: Adjusted analysis for BAN
Number of subjects: 890
Study 27429037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg
Number of subjects: 62
Study 27429037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25259643 — intervention group
Group type: EXPERIMENTAL
Intervention: Homecare training
Number of subjects: 12
Study 22051940 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Plus (n = 137) - PCP counseling every 4 months plus monthly LC visits during the first year of treatment
Number of subjects: 261
Study 22051940 — intervention group
Group type: COMPARATOR
Intervention: Basic (n = 124) - PCP counseling every 4 months only
Number of subjects: 261
Study 20613460 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (anti-inflammatory treatment)
Number of subjects: 0
Study 20613460 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 17663101 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-injection of BCG polysaccharide nuclear acid (BCG-PSN)
Number of subjects: 200
Study 17663101 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of BCG-PSN
Number of subjects: 200
Study 17663101 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of interferon
Number of subjects: 200
Study 17663101 — intervention group
Group type: COMPARATOR
Intervention: No treatment (blank control group)
Number of subjects: 200
Study 16105152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 100 mg
Number of subjects: 129
Study 16105152 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 100 mg
Number of subjects: 129
Study 12139216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (200 mg for 3 days)
Number of subjects: 275
Study 12139216 — intervention group
Group type: COMPARATOR
Intervention: Quinfamide (100 mg for 1 day), mebendazole (200 mg for 3 days), or both
Number of subjects: 275
Study 10199534 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) before cardiopulmonary bypass and before declamping of the aorta (MPS group, n = 11)
Number of subjects: 21
Study 10199534 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 21
Study 10199534 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS group)
Number of subjects: 21
Study 10199534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 7882789 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair of colon injuries
Number of subjects: 200
Study 7882789 — intervention group
Group type: COMPARATOR
Intervention: Fecal diversion
Number of subjects: 200
Study 2182822 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive taste and reward system
Number of subjects: 22
Study 437665 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin forte dragées, 2 dragées three times daily for six weeks
Number of subjects: 70
Study 30597025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg)
Number of subjects: 0
Study 30597025 — intervention group
Group type: COMPARATOR
Intervention: Standard rifampicin (10 mg/kg daily)
Number of subjects: 0
Study 28011099 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (70 min/week of at least moderate intensity)
Number of subjects: 46
Study 28011099 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 46
Study 28011099 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 25881975 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-based anticoagulation (RCA)
Number of subjects: 103
Study 25881975 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 103
Study 23703406 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous neurolysis
Number of subjects: 90
Study 23703406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21112671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% nitrofurazone
Number of subjects: 71
Study 21112671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% polihexanide
Number of subjects: 71
Study 21112671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Number of subjects: 71
Study 19174717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IB)
Number of subjects: 30
Study 19174717 — intervention group
Group type: COMPARATOR
Intervention: Macular grid laser photocoagulation (GLP)
Number of subjects: 30
Study 16882889 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strength training (squats on a 25 degrees decline board, 3 sets of 15 repetitions, twice daily for 12 weeks)
Number of subjects: 35
Study 16882889 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (open patellar tenotomy with rehabilitation)
Number of subjects: 35
Study 14687242 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA group (n = 18)
Number of subjects: 50
Study 14687242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-preterm group (n = 15)
Number of subjects: 50
Study 14687242 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 17)
Number of subjects: 50
Study 11748758 — intervention group
Group type: EXPERIMENTAL
Intervention: acute levodopa (L-dopa) challenge
Number of subjects: 1
Study 11748758 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1
Study 9269364 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg suppository diclofenac before surgical incision and morphine infusion 1.5 mg per hour postoperatively
Number of subjects: 60
Study 9269364 — intervention group
Group type: COMPARATOR
Intervention: Morphine infusion 1.5 mg per hour postoperatively
Number of subjects: 60
Study 8111804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg BID
Number of subjects: 208
Study 8111804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg BID
Number of subjects: 208
Study 8111804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 3448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Kirschner wires
Number of subjects: 86
Study 3448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Threaded Kirschner wires
Number of subjects: 86
Study 3448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical screw
Number of subjects: 86
Study 3448989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 3448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 86
Study 29746536 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss attempts
Number of subjects: 555
Study 29746536 — intervention group
Group type: EXPERIMENTAL
Intervention: Following a specific dietary regimen
Number of subjects: 555
Study 29746536 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identification as overweight
Number of subjects: 555
Study 27100753 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 cc blood donation
Number of subjects: 0
Study 27100753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no blood donation)
Number of subjects: 0
Study 25715047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 52
Study 25715047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24026316 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of methylprednisolone
Number of subjects: 111
Study 24026316 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone
Number of subjects: 111
Study 24026316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 21038023 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 21038023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18042410 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ASU
Number of subjects: 664
Study 15842188 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFP behavioral change effort
Number of subjects: 94
Study 11834948 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance information (G)
Number of subjects: 174
Study 11834948 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 174
Study 11834948 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence (good vs non-adherent)
Number of subjects: 174
Study 10024963 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-cushioned ankle brace (Air-Stirrup, Aircast)
Number of subjects: 73
Study 10024963 — intervention group
Group type: COMPARATOR
Intervention: Compression bandage
Number of subjects: 73
Study 10024963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Air-cushioned ankle brace and Compression bandage)
Number of subjects: 73
Study 7570257 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser and Ultrasounds
Number of subjects: 68